Nuwellis, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US67113Y4052
USD
2.63
0.38 (16.63%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Nuwellis, Inc. stock-summary
stock-summary
Nuwellis, Inc.
Pharmaceuticals & Biotechnology
CHF Solutions, Inc. is a medical device company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex FlexFlow and the Aquadex SmartFlow systems are collectively called as Aquadex System. The Aquadex System is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System consists of: a console, a piece of capital equipment containing electromechanical pumps and an liquid crystal display (LCD) screen; a one-time disposable blood set, an integrated collection of tubing, filter, sensors, and connectors that contain and deliver the blood from and back to the patient; and a disposable catheter, a small, dual-lumen extended length catheter designed to access the peripheral venous system of the patient.
Company Coordinates stock-summary
Company Details
12988 Valley View Rd , EDEN PRAIRIE MN : 55344-3657
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.84%)

Foreign Institutions

Held by 4 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. John Erb
Chairman of the Board
Mr. Warren Watson
Lead Independent Director
Mr. Steven Brandt
Independent Director
Dr. Maria Costanzo
Independent Director
Mr. Jon Salveson
Independent Director
Mr. Gregory Waller
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2 Million
(Quarterly Results - Jun 2025)
Net Profit:
-13 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 4 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.47

stock-summary
Return on Equity

227.94%

stock-summary
Price to Book

-0.48